FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), an engineered oncolytic viral therapy, for patients with advanced, treatment-resistant melanoma. This offers a new treatment option for a difficult-to-treat cancer.
Read original →